# Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

> **NCT06414889** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (estimated)

## Conditions studied

- RUNX1 Familial Platelet Disorder

## Interventions

- **DRUG:** G-CSF (filgrastim or biosimilar)
- **PROCEDURE:** Apheresis
- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT06414889
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414889, "Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06414889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*